Frontpage Hero

Because we care, we need to act

Apply to Sobi Scientific Innovation Awards

The Sobi Scientific Innovation Awards aim to recognise innovation and scientific excellence.
Sobi Capital Markets Day

Sobi Capital Markets Day - 14 May

The recorded version of the capital markets day as well as the slides from the persentations are now available.
Sobi 2018 Annual and Sustainability Report

Sobi 2018 Annual and Sustainability Report

"2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see this as an important stepping stone. In the Annual and Sustainability Report, we outline how the strong growth we delivered throughout 2018 is fuelling our vision of becoming global leaders in providing innovative treatments that transform life for people with rare diseases".

Press releases

Sobi™ presents data at the ISTH 2019: The 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6 – 10 July 2019, focusing on the use of Elocta® and Alprolix® in clinical settings such as treatment switches from on demand to...

06/25/2019 - 13:45

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces that new research demonstrating the effects of emapalumab in patients with macrophage activation syndrome (MAS), a form of secondary haemophagocytic lymphohistiocytosis (HLH) complicating systemic juvenile...

06/18/2019 - 09:00
  • Intended reorganisation of R&D to increase focus and investment in late-stage development
  • Plans to establish centres of excellence in Sweden and Switzerland
  • The new focus of the R&D organisation would lead to annual savings of SEK 200–300  M in 2020 to be reallocated to...
06/12/2019 - 13:10

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The...

06/12/2019 - 13:00
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden